Our primary research interest is to develop effective, safe, and off-the-shelf cancer immunotherapy. Adoptive immunotherapy is an especially promising therapeutic approach as represented by recent success of chimeric antigen receptor (CAR)-engineered T cell therapy against hematologic malignancies. Our overarching goal is to cure cancer by using the immune system.
Professor Yuki Kagoya, M.D., Ph.D.